STAT+: Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies
A man with muscular dystrophy who was first in line to receive an experimental gene…
Category: CRISPR
Here’s why we’re not prepared for the next wave of biotech innovation
The first time I remember hearing the words “biology’s century,” it was a sales pitch….
STAT+: A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments
Editas Medicine’s new leadership team on Wednesday reiterated a promise to deliver clinical updates on…
STAT+: A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more
Sure, you’ve heard of CRISPR. But it’s 2022. The acronym you need to know now…
STAT+: Biotech turns to new and strange viruses to overcome gene therapy’s limitations
CAMBRIDGE, Mass. — The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a…
Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0
When is a pandemic “over?” Did biotech over-SPAC? And what can’t be CRISPR’d? We cover…
STAT+: New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors
A new CRISPR startup — backed by some big names in venture capital — is…
STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
Intellia Therapeutics said Friday the first six patients to receive its CRISPR-based treatment for a…
Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’
Can CRISPR edit out a heart attack? What happens on #GutTok? And is health care…
Opinion: Secrecy: A demon of gene therapy’s past bedevils its future
Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough…
STAT+: Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk
What happens when you CRISPR people? Few questions generated more contentious discussion in biotech in…
.jpg)
CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissor’s first decade
On June 28, 2012, a joint press release went out from the U.S. Department of…
STAT+: Updated study results show a CRISPR treatment for blood diseases continues to benefit patients
Updated results announced Saturday from two clinical trials involving an experimental, genome-editing treatment showed prolonged…
STAT+: A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal
Caribou Biosciences said Thursday that its CRISPR-edited T-cell therapy induced complete remissions in four of…
Opinion: It’s time for Congress to stop blocking mitochondrial replacement therapy
Australia has become the second country in the world to explicitly authorize and regulate mitochondrial…
In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Earlier this month, the U.S. Patent and Trademark Office ruled that CRISPR patents key to…
STAT+: New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal
More than three years after the now-infamous Chinese scientist He Jiankui sent shockwaves around the…
.jpg)
Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Is “test to treat” too good to be true? Does it really matter who gets…
Opinion: Rediscovering a language of healing that doesn’t require ‘cure’
I am a biotech investor and entrepreneur. But more central to my worldview is that…
STAT+: 3 burning questions spurred by the big CRISPR patent ruling
On Monday, the U.S. Patent and Trademark Office ruled that CRISPR patents key to developing…
STAT+: UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies
Ending the latest chapter in a years-long legal battle over who invented CRISPR, the U.S….
STAT+: Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment
Intellia Therapeutics said Monday that its CRISPR-based therapy for a genetic nerve disorder reduced the…
STAT+: With new trial data coming on Monday, Intellia CEO talks up the future of in vivo gene editing
In 1996, 32,655 Americans died from AIDS. A year later, that number was 16,685. The…
Virtual Event: CRISPR Quest
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET…
STAT+: 3 CRISPR editing innovations to watch in 2022
During the first year of the Covid-19 pandemic, many of the world’s scientists — including…
STAT+: New CRISPR tools could fix diseases caused by large DNA rearrangements, scientists report
Ever since the now Nobel-winning discovery of CRISPR genome editing in 2020, scientists have been…
STAT+: Editas CRISPR treatment improved vision for one patient, but not others, early data show
An experimental CRISPR-based treatment from Editas Medicine led to meaningful improvements in the functional vision…
Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest
Harvard scientist George Church, a pioneer of both DNA sequencing and gene editing, has been…
STAT+: A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR
On a chilly morning last November, Michael Segel stepped through the glass doors of the…
Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too
While Covid-19 struck a blow to a vast number of clinical trials around the world,…
STAT+: Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails
The discovery of a rare genetic mutation that seems to protect certain people from becoming…
Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021
How much can CRISPR really do? Has the FDA been totally honest? And is it…
STAT+: In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy
In a major milestone for the still-young field of genome editing, Intellia Therapeutics said Saturday that…
STAT+: CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments
Off-the-shelf treatments for cancer made from genetically engineered T cells and natural killer, or NK,…
STAT+: Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation
Right now, trillions of donut-shaped red blood cells are whizzing through your arteries, ferrying oxygen…
Opinion: STAT+: Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more
In this week’s episode of the “First Opinion Podcast,” STAT’s Patrick Skerrett talks with journalist,…
Opinion: Listen: Walter Isaacson on CRISPR rivals and a Covid truce
In this week’s episode of STAT’s “First Opinion Podcast,” I talk with journalist, historian, and…
Opinion: CRISPR rivals put patents aside to help in fight against Covid-19
In early January 2020, Feng Zhang, a gene-editing researcher at the Broad Institute of MIT…
Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation
When are we getting more Covid-19 vaccine data? Is CRISPR having a dot-com moment? And…
Opinion: Mother Nature is not ‘the ultimate bioterrorist’
Despite the menacing track record of emerging pathogens, “Mother Nature is the world’s worst bioterrorist,”…
Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible
Ten patients treated with a CRISPR-based gene-editing therapy for the inherited blood disorders sickle cell…
STAT Plus: Patent board delivers blow to University of California over its CRISPR invention claims
Making a key ruling in a long-running battle over lucrative patent rights, a government patent…
The U.S. must do some heavy lifting to prepare for heritable genome editing
Countries contemplating giving the green light to heritable genome editing received specific guidance from an…
We’re not ready for more ‘CRISPR babies,’ expert panel warns, but it outlines steps before future attempts
Nearly two years after the birth of the first “CRISPR babies” stunned the world, an…
Virtual Event: CRISPR’s forward march
Editor’s note: A livestream of this virtual event will be posted above at 1 p.m….
Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases
Biologist David Liu was in the middle of his morning commute to the Broad Institute…
In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys
A form of CRISPR widely expected to be safer and possibly more effective that the…
STAT Plus: Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease
Verve Therapeutics, a Cambridge biotech that wants to use gene-editing to lower cholesterol, said Thursday…
Opinion: The Bio Revolution is changing business and society
Imagine a world in which we can produce meat without animals, cure previously incurable diseases…
STAT Plus: Deluge of genome editing therapies end research drought for sickle cell disease
The newest publicly traded genome editing company, Beam Therapeutics, has gotten one of its experimental…